Our study sheds light on the mechanism of action of PARP inhibitors in ATM-deficient cells and reveals that the addition of an ATR inhibitor is required to induce cell death in olaparib-treated ATM-deficient lung cancer cells. Here, ATM is linked to lung cancer.